Search company, investor...

Tissue Regeneration Systems

Founded Year



Debt | Alive

Total Raised


Last Raised

$4.09M | 9 yrs ago

About Tissue Regeneration Systems

Tissue Regeneration Systems (TRS) is commercializing a skeletal reconstruction and bone reconstruction technology for the fabrication of bioresorbable implants. These implants fully replace themselves with natural bone over time, leaving no residual implanted device; moreover, although the micro-architecture of these implants is porous for the facilitation of bone integration, they can nonetheless bear load and are strong enough to support function without the need for reinforcement from metal plates. Such structural integrity enables them to be used as an alternative to harvested, autologous bone that is fixed with metallic plates for complex skeletal reconstruction. TRS implants are also integrated with an osteoconductive coating that enhances bone regeneration and proliferation; powerful orthobiologics and bone-growing autologous cells will readily bind to this coating, allowing for a controlled biologic release to further accelerate bone formation.

Headquarters Location

46701 Commerce Center Drive

Plymouth, Michigan, 48170,

United States


Missing: Tissue Regeneration Systems's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Tissue Regeneration Systems's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Tissue Regeneration Systems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Tissue Regeneration Systems is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Tissue Regeneration Systems Patents

Tissue Regeneration Systems has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Nanomaterials, Nanotechnology, Nanoelectronics, Nanotechnologists, Legal terminology


Application Date


Grant Date



Related Topics

Nanomaterials, Nanotechnology, Nanoelectronics, Nanotechnologists, Legal terminology



Latest Tissue Regeneration Systems News

After 3-Year Partnership, DePuy Acquires TRS Scaffolding Technology

Apr 21, 2017

In 2014, Plymouth, MI-based biotech startup Tissue Regeneration Systems (TRS) began collaborating with DePuy Synthes Products , a company under the Johnson & Johnson umbrella making orthopedic products, such as the devices used in joint replacements. This week, DePuy formalized that relationship with the announcement that it has acquired TRS’s FDA-approved, 3D-printed scaffolding technology that enables the creation of patient-specific bone implants based on the patient’s CT scans that are made of materials that can be reabsorbed by the body. The terms of the deal were not disclosed. TRS will continue to operate and develop its second technology, a biomineral coating that makes implants more bone-friendly, accelerating the healing process and enhancing regeneration. TRS CEO Jim Fitzsimmons says that as part of the deal announced this week, DePuy has the right to use the TRS mineral coating technology on its 3D scaffolding, but TRS will retain ownership of it. Both technologies—3D-printed resorbable scaffolding and the biomineral coating—were originally developed at the University of Michigan and the University of Wisconsin. “It’s a terrific partnership,” Fitzsimmons says of DePuy. “It’s been a true joy working with them.” DePuy and TRS began collaborating through Johnson & Johnson Innovation , a division of the consumer healthcare products conglomerate that seeks healthtech startups to partner with and invest in as a way to help keep its product development pipeline full. Robert Urban, the global head of Johnson & Johnson Innovation, says DePuy was interested in adding new material science capabilities that would inspire greater patient satisfaction, which led it to TRS. “Being able to offer conventional solutions now in a very custom way is a new offering for us,” he explains. “We’re quite excited to fast-track commercialization and start getting it into as many patients’ lives as possible.” After spending the past nine years building up TRS, Fitzsimmons is looking forward to the company’s next phase of growth. TRS plans to pursue “much broader applications” for the biomineral coating, he says, such as the area of spinal fusions, where most implants are made of titanium or PEEK—which the human body tends to recognize as a foreign object, he says. “A biofilm can form and prevent total healing,” he adds. “That creates the potential for infection. Coating PEEK in our material turns it into something more bone-like.” Fitzsimmons says TRS is “not a commercial company,” preferring instead to partner with large entities like DePuy when it comes to getting its products on the market. The seven-person team plans to continue down the partnership path as it further develops its coating. “Next, we’re focusing on R&D initiatives,” he says. “Our model is to work with bigger companies on commercialization, so we hope to repeat that.” Sarah Schmid Stevenson is the editor of Xconomy Detroit/Ann Arbor. You can reach her at 313-570-9823 or Follow @XconomyDET_AA

Tissue Regeneration Systems Frequently Asked Questions (FAQ)

  • When was Tissue Regeneration Systems founded?

    Tissue Regeneration Systems was founded in 2008.

  • Where is Tissue Regeneration Systems's headquarters?

    Tissue Regeneration Systems's headquarters is located at 46701 Commerce Center Drive, Plymouth.

  • What is Tissue Regeneration Systems's latest funding round?

    Tissue Regeneration Systems's latest funding round is Debt.

  • How much did Tissue Regeneration Systems raise?

    Tissue Regeneration Systems raised a total of $10.72M.

  • Who are the investors of Tissue Regeneration Systems?

    Investors of Tissue Regeneration Systems include Venture Investors and Wisconsin Alumni Research Foundation.

  • Who are Tissue Regeneration Systems's competitors?

    Competitors of Tissue Regeneration Systems include Biorez, MedShape, TissueTech, REGENESIS BIOMEDICAL, Acelity and 13 more.

Compare Tissue Regeneration Systems to Competitors


Regenesis is engaged in the development, manufacturing, and sale of biomedical devices that promote healing and skin wound closure more quickly and cost-effectively than existing standards of wound treatment. The company's devices are based on its Cell Proliferation Induction (CPI) technology, in which electromagnetic signals trigger the repair and regeneration of soft tissue cells.

Pegasus Biologics

Pegasus Biologics is developing advanced bioimplants for soft tissue reinforcement for orthopedics, sports medicine, neurosurgical and spine applications

Transcutaneous Technologies

Developing, manufacturing, selling and exporting transcutaneousndevices which will put physiologically active substances intonsubcutaneous tissue applying the theory of electrophoresis. Developing, manufacturing, selling, exporting and importing cosmetic devices, health enhancement devices and medical devices. nnDeveloping, manufacturing, selling, exporting and importing cosmetics. All businesses that are incidental or related to the businesses stated nin the preceding items.


NICO develops technology for the field of minimally invasive neurosurgery, including skull base and spinal surgery. The company's technology and products are designed and developed to impact patients' lives, families, caregivers, and health system providers. It provides patented technologies that integrate imaging and intervention for approaches to brain surgery. NICO was founded in 2007 and is based in Indianapolis, Indiana.

Connective Orthopaedics

Connective Orthopaedics is a medical device company focused on the repair of soft tissue injuries.


EA Devices is developing a high-powered needle for penetrating bone, where the company believes competition is low and present biopsy approaches have known deficiencies (operator control and fatigue, and patient anxiety and pain).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.